ReviewFrontiers in cardiovascular medicine2025
Key inflammatory players for infarcted mass and cardiac remodeling after acute myocardial infarction.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Leukocyte activation and inflammation in acute myocardial infarction: novel insights from cell population data.Frontiers in immunology · 2026Article
- Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis has been defined as an inflammatory disease. As observed during acute infections, excess inflammatory activity is associated with disease severity and mortality. After myocardial infarction, several waves of inflammatory cells play a crucial role in infarct size and cardiac remodeling. In the short and long term, subtypes of inflammatory cells and cytokines released orchestrate the healing and stability of coronary disease. In recent years, some anti-inflammatory therapies have been shown to reduce the residual cardiovascular risk. Furthermore, some medications for treating risk factors and adoption of healthy lifestyle have decreased inflammatory markers and cardiovascular outcomes. In this complex network of possibilities, multiple interventions and not just on specific cell type or cytokine may provide better results. Finally, mild or moderate inflammatory activity appears necessary for better recovery and survival after acute myocardial infarction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.